Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 ...

In a gold-standard model of obesity, treatment with ARD-201 resulted in approximately 19% body weight reduction after 30 days of treatment. ARD-201 was also associated with attenuated weight regain ...

The option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan and was granted as an inducement material to the employee’s employment with Aardvark in ...

Summary: Preclinical and clinical data support the continued development of ARD-201 to attenuate weight gain, promote weight loss, and help maintain weight after the discontinuation of glucagon-like ...

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate ...

Live webcasts of each presentation will be accessible on the company’s website, www.aardvarktherapeutics.com, under the investors section and an archived recording will be available on the website for ...

Aardvark will be hosting an investor webinar on Wednesday, November 5, 2025 from 5:00 to 7:00 p.m. ET. Aardvark will provide an overview of ARD-101, ARD-201 and WE-868 data presented at ObesityWeek, ...

New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today’s obe ...

Each option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan, and was granted as an inducement material to each employee’s employment with Aardvark in ...